Precision BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Precision BioSciences, Inc.
ASGCT Late Breakers: Pfizer’s Duchenne Results Underwhelm As Next-Gen Approaches Emerge
The congress’s late breakers highlight progress across cell and gene platforms and diseases, and Duchenne is in the spotlight as Sarepta’s SRP-9001 could soon gain accelerated approval.
Intellia Says Sickle Cell Therapy Still ‘Wide Open’ As Novartis And Others Exit
A long-anticipated pruning back of the ev vivo gene therapy pipeline for sickle cell disease has arrived with Novartis, Graphite Bio and Sangamo each dropping projects, but some challengers are looking ahead to a future of in vivo approaches to the condition.
Lilly Builds On Gene Therapy Focus With Akouos Takeout
With the planned $487m acquisition of sensorineural-focused Akouos, Lilly makes its second gene therapy M&A play in two years, on top of partnering/financing activity in the space.
Confidence In SpringWorks Grows With Expanded GSK Deal And Nirogacestat Plans
SpringWorks is on course to bring nirogacestat to market by next year – and could play a pivotal role in making BCMA-targeting drugs a success.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Elo Life Systems
- Precision PlantSciences
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.